Relative Efficacy of Knee Osteoarthritis Treatments: Are All Placebos Created Equal?
Authors: Lisa A. Mandl, Elena Losina
Journal: Annals of Internal Medicine (2015)

Editorials6 January 2015Relative Efficacy of Knee Osteoarthritis Treatments: Are All Placebos Created Equal?Lisa A. Mandl, MD, MPH and Elena Losina, PhDLisa A. Mandl, MD, MPHFrom Hospital for Special Surgery, Weill Cornell Medical School, New York, New York, and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. and Elena Losina, PhDFrom Hospital for Special Surgery, Weill Cornell Medical School, New York, New York, and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M14-2636 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Almost 40% of the U.S. population older than 45 years has some degree of knee osteoarthritis (OA), and the estimated lifetime risk for knee OA is 14% (1). This number is likely to rise even further. Obesity is skyrocketing, with an estimated 65 million more obese U.S. adults by 2030 (2). Greater participation in sports has led to high rates of anterior cruciate ligament rupture, and up to half of persons with this injury will develop symptomatic knee OA (3). Most important, the U.S. population is aging, with at least 92 million persons older than 65 years by 2060.This ...References1. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res (Hoboken). 2013;65:703-11. [PMID: 23203864] doi:10.1002/acr.21898 CrossrefMedlineGoogle Scholar2. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378:815-25. [PMID: 21872750] doi:10.1016/S0140-6736(11)60814-3 CrossrefMedlineGoogle Scholar3. Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med. 2007;35:1756-69. [PMID: 17761605] CrossrefMedlineGoogle Scholar4. Losina E, Dervan EE, Daigle ME, Katz JN. Studies of pain management in osteoarthritis: bedside to policy. Osteoarthritis Cartilage. 2013;21:1264-71. [PMID: 23973140] doi:10.1016/j.joca.2013.04.013 CrossrefMedlineGoogle Scholar5. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152:S2-15. [PMID: 20961685] doi:10.1016/j.pain.2010.09.030 CrossrefMedlineGoogle Scholar6. Rutjes AW, Jüni P, daCosta BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012;157:180-91. [PMID: 22868835] doi:10.7326/0003-4819-157-3-201208070-00473 LinkGoogle Scholar7. American Board of Internal Medicine; American Academy of Orthopedic Surgeons. Treating osteoarthritis of the knee: popular supplements don't work. Choosing Wisely Campaign. Philadelphia: American Board of Internal Medicine Foundation; 2014. Accessed at www.choosingwisely.org/doctor-patient-lists/treating-osteoarthritis-of-the-knee on 24 November 2014. Google Scholar8. Millennium Research Group. Global hyaluronic acid market to grow to $2.5 billion by 2017. Toronto, Ontario, Canada: Millennium Research Group; 2013. Accessed at http://mrg.net/News-and-Events/Press-Releases/Hyaluronic-Acid-Market-012813.aspx on 14 November 2014. Google Scholar9. Grand View Research. Global glucosamine market by application (nutritional supplements, food & beverages, dairy products) expected to reach USD 1,246.4 million by 2020. San Francisco: Grand View Research; 2014. Accessed at www.grandviewresearch.com/press-release/global-glucosamine-market 14 November 2014. Google Scholar10. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis. A systematic review and network meta-analysis. Ann Intern Med. 2015;162:46-54. doi:10.7326/M14-5129 LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Lisa A. Mandl, MD, MPH; Elena Losina, PhDAffiliations: From Hospital for Special Surgery, Weill Cornell Medical School, New York, New York, and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-2636.Corresponding Author: Lisa A. Mandl, MD, MPH, Hospital for Special Surgery, Weill Cornell Medical School, 535 East 70th Street, New York, NY 10021; e-mail, MandlL@HSS.EDU.Current Author Addresses:Dr. Mandl: Hospital for Special Surgery, Weill Cornell Medical School, 535 East 70th Street, New York, NY 10021.Dr. Losina: Department of Orthopedic Surgery, Brigham and Women's Hospital, Bc-4016, 75 Francis Street, Boston, MA 02115. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Effectiveness of Pharmacologic Interventions for Knee Osteoarthritis Raveendhara R. Bannuru , Christopher H. Schmid , David M. Kent , Elizaveta E. Vaysbrot , John B. Wong , and Timothy E. McAlindon Comparative Effectiveness of Pharmacologic Interventions for Knee Osteoarthritis Raveendhara R. Bannuru , Christopher H. Schmid , David M. Kent , Elizaveta E. Vaysbrot , John B. Wong , and Timothy E. McAlindon Metrics Cited byUltrasound-guided intra-articular injection of expanded umbilical cord mesenchymal stem cells in knee osteoarthritis: a safety/efficacy study with MRI dataTenoxicam loaded hyalcubosomes for osteoarthritisThe evidence of surgery delay after viscosupplementation is increasingUmbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II TrialEfficacy of Sodium Hyaluronate for Temporomandibular Joint Disorder by Single-Puncture ArthrocentesisNutraceutical/Alternative Remedies in the Management of OAPlatelet-Rich Plasma Intra-articular Knee Injections Show No Superiority Versus ViscosupplementationPharmacologic Interventions for Knee OsteoarthritisDonald M. Marcus, MD 6 January 2015Volume 162, Issue 1Page: 71-72KeywordsChondroitinDecision makingDisclosureKneesNetwork analysisOsteoarthritisPatient advocacySulfatesSurgeryToxicity ePublished: 6 January 2015 Issue Published: 6 January 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...